Navigation Links
US Hospitals Increasingly Colonized by Drug-resistant Germs

Concern is rising in the US over increasing lack of hygiene in hospitals, resulting in a virtual invasion by the drug-resistant staph bacteria, also called the superbugs.

At least 30,000 U.S. hospital patients may be carrying in them the superbugs at any given time, according to a survey released Monday by the Association for Professionals in Infection Control and Epidemiology.

The estimate is about 10 times the rate that some health officials had previously estimated.

Called methicillin-resistant staphylococcus aureus, or MRSA, these staph germs can cause skin infections that in rare cases have led to pneumonia, bloodstream infections and a painful, flesh-destroying condition.

Actually, about 25% of people normally carry staph in the nose, mouth, genitals, and anal area. The foot is very prone to pick up bacteria from the floor. The infection often begins with a little cut, which gets infected with bacteria.

These staph infections range from a simple boil to antibiotic-resistant infections to flesh-eating infections. The difference between all these is how deep and how fast the infection spreads, and how treatable it is with antibiotics.

MRSA is hard to treat because the bacteria have developed resistance to the penicillin drug family.

The antibiotic-resistant infections are more common in North America, because of overuse of antibiotics.

Some federal health officials said they had not seen the APICE study and could not comment on its methodology or its prevalence. But they welcomed added attention to the problem.

"This is a welcome piece of information that emphasizes that this is a huge problem in health care facilities, and more needs to done to prevent it," said Dr. John Jernigan, an epidemiologist with the U.S. Centers for Disease Control and Prevention.

Past studies have looked at how common the superbug is in specific patient groups, such as emerge
'"/>




Page: 1 2 3 4

Related medicine news :

1. Apollo Hospitals to consider listing on US Bourses in 2003
2. Apollo Hospitals Collaborates With Histostem For Stem Cell Therapy
3. Indian Hospitals – A Destination For Quality Medical Care
4. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
5. Quality Awareness In Hospitals Can Reduce Mortality Rate Of Patients
6. First PET-CT guided radiotherapy in India was performed by Apollo Hospitals
7. Delhi Government To Interlink All Major Hospitals Through e-Governance
8. Global Hospitals coming to city of Joy
9. Indias Hospitals Among The Best, Says Renuka Chowdhury
10. Apollo Hospitals Short-listed to Provide Diagnostics in the UK
11. Apollo Hospitals to invest Rs 350 cr to add 1,800 beds
Post Your Comments:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sundia MediTech Appoints Dr Chen Chen as Senior VP of Chemistry 50700 1Sundia MediTech Appoints Dr Chen Chen as Senior VP of Chemistry 50700 2Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 1Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 2Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 3Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 50697 4Dr Julian Whitaker Featured on Searchjointpain com 50694 1Dr Julian Whitaker Featured on Searchjointpain com 50694 2